Compare ENVA & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENVA | FOLD |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.5B |
| IPO Year | 2011 | 2006 |
| Metric | ENVA | FOLD |
|---|---|---|
| Price | $190.01 | $14.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $185.71 | $27.25 |
| AVG Volume (30 Days) | 184.2K | ★ 2.5M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.05 | 50.00 |
| EPS | ★ 3.46 | N/A |
| Revenue | ★ $3,151,653,000.00 | N/A |
| Revenue This Year | $149.64 | $20.50 |
| Revenue Next Year | $16.42 | $18.59 |
| P/E Ratio | $54.79 | ★ N/A |
| Revenue Growth | ★ 18.58 | N/A |
| 52 Week Low | $94.27 | $5.66 |
| 52 Week High | $191.22 | $14.50 |
| Indicator | ENVA | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 71.71 | 74.18 |
| Support Level | $154.76 | $14.21 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 5.73 | 0.02 |
| MACD | 2.76 | -0.00 |
| Stochastic Oscillator | 89.76 | 100.00 |
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.